Literature DB >> 19546168

Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis.

Zsófia Tömböl1, Peter M Szabó, Viktor Molnár, Zoltán Wiener, Gergely Tölgyesi, János Horányi, Peter Riesz, Peter Reismann, Attila Patócs, István Likó, Rolf-Christian Gaillard, András Falus, Károly Rácz, Peter Igaz.   

Abstract

MicroRNAs (miRs) are involved in the pathogenesis of several neoplasms; however, there are no data on their expression patterns and possible roles in adrenocortical tumors. Our objective was to study adrenocortical tumors by an integrative bioinformatics analysis involving miR and transcriptomics profiling, pathway analysis, and a novel, tissue-specific miR target prediction approach. Thirty-six tissue samples including normal adrenocortical tissues, benign adenomas, and adrenocortical carcinomas (ACC) were studied by simultaneous miR and mRNA profiling. A novel data-processing software was used to identify all predicted miR-mRNA interactions retrieved from PicTar, TargetScan, and miRBase. Tissue-specific target prediction was achieved by filtering out mRNAs with undetectable expression and searching for mRNA targets with inverse expression alterations as their regulatory miRs. Target sets and significant microarray data were subjected to Ingenuity Pathway Analysis. Six miRs with significantly different expression were found. miR-184 and miR-503 showed significantly higher, whereas miR-511 and miR-214 showed significantly lower expression in ACCs than in other groups. Expression of miR-210 was significantly lower in cortisol-secreting adenomas than in ACCs. By calculating the difference between dCT(miR-511) and dCT(miR-503) (delta cycle threshold), ACCs could be distinguished from benign adenomas with high sensitivity and specificity. Pathway analysis revealed the possible involvement of G2/M checkpoint damage in ACC pathogenesis. To our knowledge, this is the first report describing miR expression patterns and pathway analysis in sporadic adrenocortical tumors. miR biomarkers may be helpful for the diagnosis of adrenocortical malignancy. This tissue-specific target prediction approach may be used in other tumors too.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19546168     DOI: 10.1677/ERC-09-0096

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  73 in total

Review 1.  The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases.

Authors:  John R Finnerty; Wang-Xia Wang; Sébastien S Hébert; Bernard R Wilfred; Guogen Mao; Peter T Nelson
Journal:  J Mol Biol       Date:  2010-08-01       Impact factor: 5.469

Review 2.  Adrenocortical carcinoma: the dawn of a new era of genomic and molecular biology analysis.

Authors:  R Armignacco; G Cantini; L Canu; G Poli; T Ercolino; M Mannelli; M Luconi
Journal:  J Endocrinol Invest       Date:  2017-10-28       Impact factor: 4.256

3.  Emerging therapy for adrenocortical carcinoma.

Authors:  Rachel D Aufforth; Naris Nilubol
Journal:  Int J Endocr Oncol       Date:  2014

Review 4.  Minireview: miRomics in endocrinology: a novel approach for modeling endocrine diseases.

Authors:  Péter M Szabó; Henriett Butz; Péter Igaz; Károly Rácz; László Hunyady; Attila Patócs
Journal:  Mol Endocrinol       Date:  2013-01-24

5.  Antitumoral effects of 9-cis retinoic acid in adrenocortical cancer.

Authors:  Diana Rita Szabó; Kornélia Baghy; Peter M Szabó; Adrienn Zsippai; István Marczell; Zoltán Nagy; Vivien Varga; Katalin Éder; Sára Tóth; Edit I Buzás; András Falus; Ilona Kovalszky; Attila Patócs; Károly Rácz; Peter Igaz
Journal:  Cell Mol Life Sci       Date:  2013-06-27       Impact factor: 9.261

Review 6.  HypoxamiRs and cancer: from biology to targeted therapy.

Authors:  Harriet E Gee; Cristina Ivan; George A Calin; Mircea Ivan
Journal:  Antioxid Redox Signal       Date:  2013-11-22       Impact factor: 8.401

7.  Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.

Authors:  Mabrouka Doghman; Abeer El Wakil; Bruno Cardinaud; Emilie Thomas; Jinling Wang; Wei Zhao; Maria Helena C Peralta-Del Valle; Bonald C Figueiredo; Gerard P Zambetti; Enzo Lalli
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

Review 8.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

9.  Fluorescence activated cell sorting followed by small RNA sequencing reveals stable microRNA expression during cell cycle progression.

Authors:  Vince Kornél Grolmusz; Eszter Angéla Tóth; Kornélia Baghy; István Likó; Ottó Darvasi; Ilona Kovalszky; János Matkó; Károly Rácz; Attila Patócs
Journal:  BMC Genomics       Date:  2016-05-27       Impact factor: 3.969

10.  MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.

Authors:  Dhaval Patel; Myriem Boufraqech; Meenu Jain; Lisa Zhang; Mei He; Krisana Gesuwan; Neelam Gulati; Naris Nilubol; Tito Fojo; Electron Kebebew
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.